GH

Guardant Health, Inc. (GH) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Guardant Health is a precision oncology company providing blood and tissue tests for cancer screening, monitoring, and treatment selection. Key products include the Guardant360 suite for advanced cancer, Guardant Reveal for early-stage recurrence monitoring, and the Shield blood test for colorectal cancer screening. In Q2 2026, the company received FDA approval for its Guardant360 Liquid CDx test, integrating genomic and epigenomic insights.

Key Financial Metrics

Note: Revenue growth was driven by a 257% increase in Screening revenue and a 38% increase in Oncology revenue. Gross margin for the quarter was approximately 65.4%.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 44% year-over-year in Q2 2026. Screening revenue surged to $52.9 million (from $14.8 million) due to increased Shield test volume (66,000 tests vs. 16,000). Oncology revenue grew 38% to $219.1 million.
• Expense Increases: Sales and marketing expenses rose 59% to $190.0 million, driven by commercial infrastructure expansion and marketing for Shield and oncology products. General and administrative expenses increased 23% to $61.7 million, largely due to higher stock-based compensation.
• Debt Structure: The company holds $490.7 million in 2027 Notes, $600.0 million in 2031 Notes, and $402.5 million in 2033 Notes. The 2031 Notes became convertible in Q2 2026 as the stock price exceeded 130% of the conversion price, though no conversions were received as of July 24, 2026.
• Acquisition: In December 2025, the company acquired MetaSight Diagnostics for $93.0 million in total consideration, adding to goodwill and in-process R&D assets.

Guidance, Outlook, and Risks

• Outlook: Management expects continued investment in R&D, clinical studies (including the SOLAR and SHIELD LUNG studies), and international expansion. The company anticipates operating losses to continue in the near term as it scales operations.
• Liquidity: As of June 30, 2026, the company held approximately $1.2 billion in cash, cash equivalents, and restricted cash. Management believes this is sufficient to meet requirements for more than 12 months.
• Legal Contingencies:
  • TwinStrand/University of Washington: A jury verdict awarded plaintiffs $83.4 million in damages plus a 6% ongoing royalty. The company is appealing and estimates a potential loss range of $0 to $250 million. A liability of $83.4 million was recorded previously.
  • Natera: The company won a $292.5 million verdict for false advertising, though Natera is appealing. The court affirmed a total damages award of $287.0 million post-trial.
  • False Claims Act: The company is cooperating with a civil investigative demand from the U.S. Attorney for the Southern District of Florida regarding billing to federally funded programs.
• Risks: Key risks include reimbursement variability from payers, patent litigation outcomes, and the ability to maintain commercial momentum for new products like Shield MCD.

Investor Verification Checklist

• Verify the status of the TwinStrand patent appeal and the potential impact of the 6% ongoing royalty on future margins.
• Monitor reimbursement rates for the Shield test, particularly following the recent UnitedHealth Group coverage update effective August 1, 2026.
• Assess the convertibility of the 2031 Notes and potential dilution if holders elect to convert given the stock price performance.
• Review the progress of the SOLAR study (Shield post-FDA approval) and SHIELD LUNG study for clinical validation data.
• Track operating cash flow burn relative to the $1.2 billion cash balance to confirm the 12-month liquidity runway.